ALYI and KALY Shorts Double Down In Desperate Attempt To Hold On To Raging Rally; Get In Before The Buy-In

New York, NY -- April 9, 2019 -- InvestorsHub NewsWire -- www.nextbigticker.com -- The short selling against a rally in Alternet Systems, Inc. (USOTC: ALYI) and Kali-Extracts, Inc. (USOTC: KALY) became apparent last week. ALYI and KALY both came out with strong news and they’ve kept the news going with one new development after another. ALYI and KALY have both broken through all technical barriers and bull rallies for both rage on. The short sellers didn’t anticipate a prolonged rally and they’re doing their best to try and hold the rallies back. The shorting is continuing as the short sellers double down in an effort to halt rallies that are showing no signs of stopping any time soon. Both ALYI and KALY indicate more big news is coming later this month on top of the major releases they have already put out. The ALYI and KALY short sales that continue to make up 50% of the trading volume as reported by FINRA are bound to run out of steam. It’s only a matter of time until short sellers have to cover and add fuel to the rallies they failed to stop. Get in before the buy-in.

ALYI management is in Kenya this weeking working on a potential $20 million order for the company’s electric motorcycles. The stock continues to react bullishly and its only a matter of time until short sellers have to buy in to cover their short sales.

ALYI has a 52-Week High of over $0.06 and an analyst recommended Target PPS of $0.09. ALYI has seen a high today of $0.05 and shows signs of bouncing back up into the $0.05 range on its way to an analyst recommended $0.09 Target PPS.

KALY revealed today a patented cannabis extraction treatment for epilepsy. This is the fourth cannabis extract treatment for a major health issue the company has revealed in the last week. The company currently has ongoing cannabis extract research and development targeting four specific health issues, Chronic Obstructive Pulmonary Disease (COPD), Type 2 Diabetes, Cancer Pain Management and Epilepsy. KALY plans to publish an online presentation with more detail on each of the treatment developments later this month.

KALY Potential PPS Run From $0.01 to $0.04 On Way To $0.10

KALY has the potential to run from its $0.01 PPS level to $0.10 in the near term. Shortly after the 2018 Q4 acquisition of the patented cannabis extraction process, the company PPS shot from sub-penny land to almost $0.04 on volume that put it in the top 20 most actively traded stocks on the OTC Market. The PPS retraced back to $0.01 and has now inched up to $0.02 in the latest rally. With KALY’s patented cannabis pharmaceutical research now coming to light, the PPS is positioned to shoot past the recent $0.04 highs to a level putting it on par with some of the other penny cannabis stock contenders. A $0.10 PPS is a reasonable milestone following the company filing its upcoming annual reported expected to include the company posting its first revenue derived from its cannabis extraction process. The company filed an extension on the 2018 annual report with the report itself now expected within the next 15 days.

KALY is providing CBD extracts for over $1 million worth of CBD infused water produced by Puration, Inc. (USOTC: PURA), and KALY has also introduced its own CBD infused gum. KALY is also implementing an extraction lab to process biomass from Nouveau’s (USOTC: NOUV) 100 acer hemp farm.

Following the acquisition of the patented cannabis extraction process late last year and the corresponding jump in price and trading volume, the OTC Markets flagged the company in response to the jump in activity. The company has responded by updating all its OTC Markets required reports. Management is likely to mitigate the OTC Market’s concerns sooner or later and see the flag removed which will likely be yet another impetus fueling a KALY PPS run.

Management engaged Goldman Small Cap Research to conduct analyst coverage of the company and file an initial analyst report: KALY Research Report

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com